TB-500 has no established human dose, and the reason is straightforward: there are no controlled human trials of it. It is a synthetic fragment marketed as related to thymosin beta-4, and the tissue-repair research that dosing is loosely modeled on was done on Tβ4 in animals, not on TB-500 in people.[1][2]
Reviewed for accuracy · Last reviewed July 7, 2026Community protocols commonly cite roughly 2 – 2.5 mg injected subcutaneously once or twice weekly, sometimes as a several-week loading phase followed by less frequent maintenance, and often paired with BPC-157. Treat these as community practice rather than a guideline. TB-500 is not FDA-approved and is on the World Anti-Doping Agency prohibited list.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.